Boston Scientific (BSX)

LGBTQ equality
A (85)
Screens
Advertising
No
Alcohol
No
Animal treatment
Yes
Anti-abortion support
No
Cannabis
No
Carbon emissions intensity
No
Coal
No
Contraceptives
No
Deforestation - financing
No
Deforestation - supply chain
No
Discrimination controversies
No
Environmental controversies
No
Factory farming
No
Fast food
No
Firearms
No
For-profit health care
No
Fossil fuel
No
Fur
No
Gambling
No
Genetic engineering
No
Health-related controversies
Yes
Human rights controversies
No
Human trafficking
No
Interest-based products
No
Interest-bearing debt
No
Interest-bearing securities
No
Iran
No
Military contracting
Yes
Misleading communication
No
Music
No
Myanmar
No
Northern Ireland (Macbride)
No
North Korea
No
No SBTI commitment
No
Nuclear
No
Oil and gas
No
Opioid controversies
No
Oppressive governments
No
Pharma controversies
No
Pork
No
Pornography
No
Predatory lending
No
Prison involvement
No
Privacy breaches
No
Pro-life
No
Russia
Yes
Single-use plastic
No
Stem cell research
Yes
Sudan
No
Sugar
No
Syria
No
Tobacco
No
Undermining US elections
No
Weapons
No
Impact

Cause BSX
Peer rank
LGBTQ equality

Name Rating
Loading...
Screens
Advertising
No
Alcohol
No
Animal treatment
Yes
Anti-abortion support
No
Cannabis
No
Carbon emissions intensity
No
Coal
No
Contraceptives
No
Deforestation - financing
No
Deforestation - supply chain
No
Discrimination controversies
No
Environmental controversies
No
Factory farming
No
Fast food
No
Firearms
No
For-profit health care
No
Fossil fuel
No
Fur
No
Gambling
No
Genetic engineering
No
Health-related controversies
Yes
Human rights controversies
No
Human trafficking
No
Interest-based products
No
Interest-bearing debt
No
Interest-bearing securities
No
Iran
No
Military contracting
Yes
Misleading communication
No
Music
No
Myanmar
No
Northern Ireland (Macbride)
No
North Korea
No
No SBTI commitment
No
Nuclear
No
Oil and gas
No
Opioid controversies
No
Oppressive governments
No
Pharma controversies
No
Pork
No
Pornography
No
Predatory lending
No
Prison involvement
No
Privacy breaches
No
Pro-life
No
Russia
Yes
Single-use plastic
No
Stem cell research
Yes
Sudan
No
Sugar
No
Syria
No
Tobacco
No
Undermining US elections
No
Weapons
No
Top metrics
Sample of top metrics driving Boston Scientific's rating for LGBTQ equality (A, relative to other companies). Hover or click on a bubble for more info. See details for all metrics in table below
Loading...
All metrics
Metrics used to rate Boston Scientific for LGBTQ equality. Click on a metric for more info
Metric Source Data Normalized
Loading...

Data status

Summary statistics on data used to rate Boston Scientific for LGBTQ equality

...

of potential metrics used

...

unique data

...

peer-average data

2 days ago

last updated

...

company filings data

...

government data

...

Ethos research

...

independent organization data
Controversies
Controversies associated with Boston Scientific. Click on a controversy for more info
Title Date Severity
Loading...
* Indicates data is an average of peer group, or industry if peer data not available. Used when data for company not available.
Normalized scores are relative to other companies. Learn more about our ratings methodology
Note that all controversies information is based on publicly-available information.
BSX Price
$40.94
Last available end-of-day price. Full disclosure
Revenue
$11.89 billion
Market cap
$62.93 billion
Public/private
Public
Hypothetical growth of $10,000
Historical performance
Company
Founded
1979
Employees
41,000
Sector
Healthcare
Industry
Healthcare Equipment
Peer group
Medical Equipment - Major Diversified
Headquarters
Ma, United States
Share classes
BSX
Mission
Dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.
Description
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Material causes
Ethos considers the following causes material for Boston Scientific, based on its industry peer group Medical Equipment - Major Diversified. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.